Efficacy of Brazilian Propolis against Herpes Simplex Virus Type 1 Infection in Mice and Their Modes of Antiherpetic Efficacies by Shimizu, Tomomi et al.
Hindawi Publishing Corporation
Evidence-Based Complementaryand Alternative Medicine
Volume 2011, Article ID 976196, 9 pages
doi:10.1155/2011/976196
Research Article
EfﬁcacyofBrazilianPropolis againstHerpesSimplexVirusType1
InfectioninMice and TheirModes ofAntiherpeticEfﬁcacies
Tomomi Shimizu,1 Youhei Takeshita,1 YasushiTakamori,1 Hisahiro Kai,2 RieSawamura,1
Hiroki Yoshida,1 Wataru Watanabe,3 AtsukoTsutsumi,4 Yong Kun Park,5 KenYasukawa,6
KojiMatsuno,2 KimiyasuShiraki,7 and Masahiko Kurokawa1
1Department of Biochemistry, School of Pharmaceutical Sciences, Kyushu University of Health and Welfare,
1714-1 Yoshino, Nobeoka, Miyazaki 882-8508, Japan
2Department of Pharmaceutical Health Sciences, School of Pharmaceutical Sciences, Kyushu University of Health and Welfare,
1714-1 Yoshino, Nobeoka, Miyazaki 882-8508, Japan
3Department of Microbiology, School of Pharmaceutical Sciences, Kyushu University of Health and Welfare,
1714-1 Yoshino, Nobeoka, Miyazaki 882-8508, Japan
4Amazonfood Ltd., 2-24-28 Ohhara, Setagaya, Tokyo 156-0041, Japan
5Department of Food Science, College of Food Engineering, State University of Campinas,
P.O. Box 6177, 13083-970 Campinas, SP, Brazil
6School of Pharmacy, Nihon University, 7-7-1 Narashinodai, Funabashi-shi, Chiba 274-8555, Japan
7Department of Virology, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan
Correspondence should be addressed to MasahikoKurokawa, b2mk@phoenix.ac.jp
Received 2 September 2010; Revised 28 February 2011; Accepted 22 March 2011
Copyright © 2011 TomomiShimizu et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Ethanol extracts (AF-06, 07, and 08, 10mg/kg) of Brazilianpropolis were administered orally to cutaneously herpes simplex virus
type 1 (HSV-1)-infected mice three times daily on days 0 to 6 after infection to evaluate their eﬃcacies against HSV-1 infection
and signiﬁcantly limited development of herpetic skin lesions. AF-07 and 08 signiﬁcantly reduced virus titers in brain and/or
skin on day 4 without toxicity, but AF-08 had no anti-HSV-1 activity in vitro. AF-06 and 08 signiﬁcantly enhanced delayed-
type hypersensitivity (DTH) to inactivated HSV-1 antigen in infected mice. Oral AF-08-administration signiﬁcantly augmented
interferon (IFN)-γ production by HSV-1 antigen from splenocytes of HSV-1-infected mice, while direct exposure of splenocytes
of infected mice to AF-06 signiﬁcantly elevated IFN-γ production in vitro. Thus, AF-08 might have components that are active
in vivo even after oral administration and those of AF-06 might be active only in vitro. Because DTH is a major host defense for
intradermal HSV-1 infection, augmentation of DTH response by AF-06 or 08, directly or indirectly, respectively, may contribute
to their eﬃcacies against HSV-1 infection. In addition, AF-06 and 07 possibly contain anti-HSV-1 components contributing to
their eﬃcacies. Such biological activities of Brazilianpropolis may be useful to analyze its pharmacologicalactions.
1.Introduction
Propolis is currently used as an alternative medicine in
the management of various ailments [1]. It has been used
worldwideasafolkmedicinesinceca.300BCandasadietary
supplement to maintain or improve human health [2–4].
Propolis is a resinous hive product and consists of a mixture
of plant exudates collected by honeybees and beeswax. The
chemical composition of propolis is complex and varies
with the area where the propolis was harvested because
of the diﬀerences in plants and honeybees. Propolis has
been reported to exhibit various biological activities, such as
antibacterial, antitumor, and immunostimulatory activities
[1, 2, 5–9]. It has been also shown to exhibit anti-inﬂuenza
virus activity in vitro [6, 10]a n da n t i h e r p e ss i m p l e xv i r u s
(HSV) activity in vitro [11, 12]. Recently, Brazilian propolis
was reported to possess anti-inﬂuenza virus activity and
to ameliorate inﬂuenza symptoms in mice [13]. Although
the eﬃcacy of a Canadian propolis ointment against genital
herpetic lesions caused by HSV type 2 in humans has been
reported [14], the anti-HSV-1 activity of propolis in vivo is
not clear.2 Evidence-Based Complementary and Alternative Medicine
We have been studying the antiviral activity of medicinal
herb extracts for their possible use in the management
of viral infection in humans. In a series of studies, we
have used a cutaneous HSV type 1 (HSV-1) infection
model in mice because it manifests various markers in the
development of the disease and because this model has been
shown to have advantages for monitoring the eﬃcacies of
natural products such as herbal medicines [15–20]. Using
this murine cutaneous infection model, we have previously
found medicinal herbs that exhibit anti-HSV-1 activity in
vitro and in vivo [15–20]. Kakkon-to, a kampo formulation
composed of seven herbs, was shown to exhibit therapeutic
anti-HSV-1 eﬃcacy in the murine model by enhancing
delayed-type hypersensitivity (DTH) response against HSV-
1 antigen as assessed by cutaneous reaction [15]. The DTH
response has been reported to be a major defense system
in intradermal HSV-1 infection [21–23]. Thus, the DTH
reaction is a useful immunological marker to evaluate the
eﬃcacy on intradermal HSV infection.
In this study, three kinds of Brazilian propolis harvested
in diﬀerent areas of Brazil were examined for their anti-
HSV-1 eﬃcacies in a cutaneous HSV-1 infection model
in mice. We found that three ethanol extracts of propolis
used in this study moderately alleviated the symptoms of
cutaneous herpetic infection. The modes of their eﬃcacies
were evaluated virologically and immunologically, and we
characterized the potential and pharmacological activities of
Brazilian propolis.
2.Materialsand Methods
2.1. Viruses and Cells. HSV-1 7401H strain [24] was propa-
gated in Vero E6 cells [16]. The infected cultures were frozen
and thawed three times and centrifuged at 3,000rpm for
15min. Their supernatants were stored at −80◦Cu n t i lu s e
[16]. Vero E6 cells were grown and maintained in Eagle’s
minimal essential medium (MEM) supplemented with 5%
and2%heat-inactivated calfserum, respectively.Splenocytes
were cultured in RPMI-1640 medium supplemented with
10% heat-inactivated fetal calf serum (FCS).
2.2. Propolis and Acyclovir (ACV). Propolis was harvested in
thediﬀerentareas ofBrazil,andthemajor botanicaloriginof
propoliswasestimatedbyourﬁeld-workasshown inTable 1.
The voucher specimens AF0305 (AF-05), AF0306 (AF-06),
AF0307 (AF-07), and AF0308 (AF-08) were deposited at
Amazonfood Co., Ltd., Tokyo, Japan. The harvested propolis
was extracted once with 95% ethanol (1:1, w/w) for 3
months at room temperature, and the ethanol-extracts
were dried in a drying machine with vacuum at 37 to
38◦C for 40 to 60min. Finally propolis paste as ethanol
extracts contained water at 5–7% (w/w), and the recovered
yields were about 30% (w/w) of original propolis. The
ethanol extracts, AF-05, 06, 07, and 08, were supplied by
Amazonfood Co., Ltd., Tokyo, Japan. These extracts were
dissolved in an appropriate volume of dimethyl sulfoxide
(DMSO) and diluted with culture medium to make various
ﬁnal concentrations for in vitro assays. The concentration
of DMSO in each medium was less than 0.2%. For in vivo
Table 1: Features of propolis.
Propolis Species∗ Family∗ State∗∗
AF-05 Baccharis
dracunculifolia DC Compositae Minas Gerais
AF-06 Baccharis erioclada DC Compositae Rio Grande
do Sul
AF-07 Baccharis
dracunculifolia DC Compositae Minas Gerais
AF-08 Myrceugenia euosma
(Berg) D. Legrand Myrtaceae Rio Grande
do Sul
∗Major botanical origins in areas where propolis was collected.
∗∗ Brazilian states where propolis was collected.
assays, these extracts were dissolved in 1% DMSO and
administered orally to mice. ACV was purchased from
Sigma-Aldrich, Japan and dissolved in distilled water.
2.3. HPLC Analysis. AF-05, 06, 07, and 08 were dissolved
in acetonitrile at 20mg/mL, and 1μL was analyzed using
coupling a reverse-phase high-performance liquid chro-
matograph (HPLC) system (LC-10ADvp, Shimadzu, Kyoto,
Japan) to a diode array detector (SPD-M10Avp, Shimadzu,
Kyoto, Japan). Separation was performed on a reverse-phase
column (COSMOSIL 5C18-MS-II, 4.6mm I.D. ×150mm,
5μm; Nacalai, Kyoto, Japan) at 40◦C using a mobile phase
of water and acetonitrile. The elution was carried out with
a nonlinear gradient of 20% acetonitrile for 10min, a linear
gradient of 20% to 100% of acetonitrile for 10 to 40min, a
nonlinear gradient of 100% of acetonitrile for 40 to 50min,
and a nonlinear gradient of20% acetonitrile for 60to 80min
at a ﬂow rate of 0.7mL/min. Spectrophotometric detec-
tion was conducted at 254nm. Quercetin (Wako, Osaka,
Japan), apigenin (Tokyo Chemical Industry, Tokyo, Japan),
kaempferol (Tokyo Chemical Industry), chrysin (Tokyo
Chemical Industry, Tokyo, Japan), acacetin (ChromaDex,
Irvine, USA),and artepillin C (Wako) were used as authentic
standards, and the major peaks eluted by HPLC were
characterized by the analysis of ultraviolet absorbance at 200
to 400nm.
2.4. Mice. BALB/c female (6 weeks old, 18–21g) mice were
purchased from Sankyo Labo Service Co., Ltd., Tokyo,
Japan, or Kyudo Animal Laboratory, Kumamoto, Japan.
The mice were housed ﬁve per cage in speciﬁc pathogen-
free conditions, with food and water ad libitum and under
a 12h light/12h dark diurnal cycle (light at 7.00 a.m.).
The temperature in the room was kept at 24 ± 2◦C.
T h em i c ew e r ea c c l i m a t e df o ra tl e a s tﬁ v ed a y sb e f o r e
starting experimental procedures. Animal studies followed
the animal experimentation guidelines of Toyama University
and Kyushu University of Health and Welfare and were
carried out in an approved biosafety level facility.
2.5. Murine HSV-1 Infection. The right midﬂank of each
mouse was clipped and depilated with a chemical depilatory,
Hair Remover (Shiseido, Co., Ltd., Tokyo, Japan). One orEvidence-Based Complementary and Alternative Medicine 3
two days later, the naked skin was scratched using a 27-
gauge needle and 5μL of HSV-1 (7401H strain) suspension
containing 2 × 105 or 1 × 106 PFU was applied to the
scariﬁed area [18, 19]. Propolis extracts (10mg/kg) or
ACV (5mg/kg) was orally administered in a volume of
0.25mL/mouse to the mice by gavage, once 4h prior to and
twice after virus infection on day 0, and 3 times daily from
day 1 to day 6 after infection. A 1% DMSO solution was
used as a control. The dosage of 30mg/kg/day of extracts for
mice corresponds to about 12 times the dosage for humans
based on body surface area [25] and used as a conventional
dose of propolis [13]. Acyclovirat 5mg/kg for mice has been
shown to be signiﬁcantly eﬀective against HSV-1 infection
in a murine infection model [18, 19]. Thus, we used the
dose of 5mg/kg for mice as a clinical dose. Ten mice in each
group were weighed daily after infection, and the changes
were calculated based on the body weight of each mouse
on day 0. The development of skin lesions and mortality
were continuously monitored every 8h daily and scored as
follows: 0, no lesion; 2, vesicles in local region; 4, erosion
and/or ulceration in local region; 6, mild zosteriform lesion;
8, moderate zosteriform lesion; 10, severe zosteriform lesion;
and 12, death. [16]. To assess the toxicity of extracts, four
miceineachuninfectedgroupwereadministeredtheextracts
at 10mg/kg following the same schedule used in infected
mice. The uninfected mice were weighed daily as described
above.
2.6. Determination of Virus Yields in Skin and Brain. Virus
yields in the skin and brain were determined in infected
mice. Mice were cutaneously infected with HSV-1 (2 ×
105 PFU/mouse), and propolis extracts were orally admin-
istered at doses of 10mg/kg following the same schedule
as described above. The brain and skin (whole lesions that
include the area (5 × 5mm) encompassing the inoculation
site) were removed under anesthesia on day 4 after infection
and homogenized in 2mL of phosphate-buﬀered saline as
described previously [18]. The homogenate was centrifuged
at 3,000rpm for 15min, and the virus yield in the super-
natant wasdetermined bytheplaqueassay onVerocells[16].
2.7.PlaqueReductionAssayandCytotoxicityAssay. Duplicate
cultures of Vero cells in 60mm plastic dishes were infected
with 100 plaque forming units (PFU)/0.2mL of HSV-1 for
1h. Then the cells were overlaid with 5mL of nutrient
methylcellulose (0.8%) medium containing various concen-
trationsofpropolisextracts. The infected cellswere ﬁxedand
stained, and the number of plaques was counted [18]. The
eﬀective concentrations for 50% plaque reduction (EC50)
were determined from a curve relating the plaque number
to the concentration of samples [18].
Cytotoxicity was examined by the growth inhibition of
Vero cells as described previously [18]. Brieﬂy, Vero cells
were seeded at a concentration of 2.5 × 104 cells/well in
24-well plates and grown at 37◦Cf o r2d a y s .T h ec u l t u r e
mediumwasreplacedwithfresh mediumcontainingextracts
at various concentrations. Cells were further grown for 2
days. The cells were treated with trypsin, and the number of
viablecells wasdetermined by thetrypan blue-exclusiontest.
Cytotoxic concentrations for 50% growth reduction (CC50)
were determined from a curve relating percent cell viability
to the concentration of drugs [18].
2.8. Footpad Swelling due to HSV-1 Antigen in Mice. To
evaluatethe eﬀectsof propolis extracts on the DTH reaction,
we examined the skin reaction against HSV-1 antigen in
mice infected with 7401H HSV-1 strain. The mice were
intradermally infected with 10μL( 7× 105 PFU/mouse)
of 7401H strain using a microsyringe with a 27-gauge
needle under anesthesia [15]. The propolis extracts were
administered totheinfected miceforday0today4following
thesamescheduleasdescribedabove.Theinfectedmicewere
challenged by injection of 10μL containing 7 × 105 PFU
of ultraviolet light- (UV-) inactivated virus antigen into a
footpad on day 4 after infection. The swelling of footpads
was measured at 24, 36, and 48h after the footpad challenge
by using an engineer’s micrometer, because DTH reaction in
intradermally HSV-1-infected mice has been reported to be
detected between 24 and 48h after challenge [15, 21].
2.9. Interferon (IFN)-γ Production from Splenocytes. Eﬀects
of the oral administration of extracts on IFN-γ production
from splenocytes of HSV-1-infected mice were examined.
Intradermally HSV-1-infected mice were orally administered
propolisextractsasdescribedabove.Onday4afterinfection,
spleens were removed under anesthesia and splenocyteswere
prepared after erythrocytolysis. The splenocytes prepared
from three mice in a group were combined, and the mixed
splenocytes were incubated at 6 × 105 cells/well in 96-well
plates, in octuplicate, in RPMI-1640 medium supplemented
with 10% heat-inactivated FCS in the presence or absence of
UV-inactivated HSV-1 antigen at 2 × 104 PFU/well for 24h
at37◦C.Cellsupernatantsoftheculturesinthe96-wellplates
w e r eh a r v e s t e da f t e rc e n t r i f u g a t i o na n ds t o r e da t−80◦Cf o r
ELISA of IFN-γ.
In addition, to examine the direct eﬀect of propolis
extracts on the IFN-γ production from splenocytes of HSV-
1-infected mice, splenocytes were prepared on day 4 after
infection from intradermally HSV-1-infected mice without
oral administration of the extracts. The splenocytes were
cultured in the presence of 0, 0.01, 0.03, 0.1, 0.3, 1, 3, and
10μg/mL of propolis extracts and in the presence or absence
of HSV-1 antigen as described above.
2.10. ELISA. IFN-γ levels in the culture supernatants were
measured using a speciﬁc ELISA kit (Ready-set-go, eBio-
science Inc., San Diego, CA) according to the manufacturer’s
instructions. The product was tested and found to conform
to all eBioscience Inc. Quality Control release speciﬁcations.
The lower limit of detectionsensitivity of the kitis 15pg/mL.
The intra- and interassay coeﬃcients of variation for these
ELISA were less than 10%.
2.11. Statistical Analysis. Statistical signiﬁcances of diﬀer-
ences between the EC50 and CC50 values and in the changes
of net body weights ofinfected mice, virus titers, net increase
infootpad thicknesses,andIFN-γ levelswereevaluatedusing
Student’s t-test. Interactions between mean scores of treated4 Evidence-Based Complementary and Alternative Medicine
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Figure 1: HPLC proﬁles of AF-05, 06, 07, and 08.
and untreated groups were analyzed using the repeated
measures two-way ANOVA. A P value of .05 or less was
considered to be signiﬁcant statistically.
3.Results
3.1. Compositions of Propolis Extracts by HPLC. Compo-
sitions of four propolis extracts (AF-05, 06, 07, and 08)
harvested in diﬀerent areas of Brazil were analyzed by HPLC.
As shown in Figure 1, the HPLC patterns of AF-05 and
AF-07 were similar and the patterns of AF-06 and AF-08
were obviously diﬀerent from those of AF-05 and 07. As
the major peaks of our HPLC proﬁles were estimated as
ﬂavonoids or prenylated phenylpropanoids in comparison
with those of Brazilian propolis as reported previously by
Park et al. [26], we detected some of them in our HPLC
system. Quercetin, apigenin, kaempferol, chrysin, acacetin,
and artepillin C as authentic compounds were eluted at 21.8,
24.6, 25.1, 29.8, 29.9, and 34.4min, respectively. The highest
peak in AF-05 and AF-07 and the second higher peak in
AF-06 were characterized as artepillin C by their analyses
of ultraviolet absorptions, and the highest peak in AF-06
was done as chrysin. As compared with AF-05, 06, and 07,
artepillinCandchrysin werenotmajorinAF-08.Weselected
AF-06, 07, and 08 as propolis with diﬀerent compositions.
3.2. Eﬃcacies of Propolis Extracts on Murine HSV-1 Infection
Model. The eﬃcacies of AF-06, 07, and 08 were examined
in a cutaneous HSV-1 infection model in mice (Figure 2).
Previously, AF-08 at 10mg/kg was signiﬁcantly eﬀective in
prolonging the survival times of inﬂuenza virus-infected
mice and in reducing virus yields in the bronchoalveolar
lavage ﬂuids of lungs in infected mice [13]. Therefore, all
threepropolisextracts(AF-06,07,and08)wereadministered
at 10mg/kg as a biologically active dose. In mice infected
withHSV-1at2 ×105 PFU/mouse,all threewere moderately
but signiﬁcantly eﬀective in limiting the development of
skin lesions for days 3.3 to 6.3 after infection (Figure 2(a),
P<. 003 by the repeated measure ANOVA), although
the mortality under propolis administration was similar
to that of the control (water-administered mice) and all
infected mice in each group examined were dead until 9
days after infection. There was no signiﬁcant diﬀerence
between the changes of net body weights of mock-infected
mice administered water and AF-06, 07, or 08 on the tenth
day after infection (2.6 ± 0.5 and 2.7 ± 0.4, 2.5 ± 0.3,
or 2.6 ± 0.2g, resp.). When mice were infected with the
higher titer of 1 × 106 PFU/mouse, the period of signiﬁcant
limitation of skin lesion developmentwas shortened, but the
development was still signiﬁcantly limited for days 3.3 to 5.0
(Figure 2(b), P<. 05 by the repeated measure ANOVA). It
was conﬁrmed that all three propolis extracts moderately
delayed the development and progression of herpetic skin
lesions in an early phase of infection without toxicity.
3.3. Anti-HSV-1 Activity of Propolis Extracts in Mice and In
Vitro. To evaluate the potential anti-HSV-1 activity of the
three propolis extracts in mice, eﬀectsofthe extractsonvirus
titers in the skin and brain of infected mice were examined
on day 4 after infection, as shown in Table 1.A F - 0 7a n d
ACV were signiﬁcantly eﬀectivein reducingvirustitersin the
skin and brain of infected mice compared with the control
(P<. 05 or P<. 001 by Student’s t-test), and AF-08 was
eﬀective in reducing virus titer in only the brain (P<. 001 by
Student’st-test). However,AF-06had no signiﬁcant eﬀecton
virus titers in either skin or brain.Evidence-Based Complementary and Alternative Medicine 5
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Figure 2: Eﬀects of propolis ethanolextracts on thedevelopment of herpetic skinlesionsofmice infected with HSV-1 cutaneously. Ten mice
in each group were infected with HSV-1 at 2 × 105 (a) or 1 × 106 (b) PFU/mouse and administered water (•), AF-06 (
￿), AF-07 (
￿), or
AF-08 (
￿) as described in text. ∗P<. 003 and ∗∗P<. 05 versus control by repeated measures ANOVA.
Table 2: Eﬀect of propolis extracts on virus titers in skin and brain
of HSV-1-infected mice.
Administration Virus titer (log10 PFU/organ)
Skin Brain
Control 6.1 ±0.07 2.2 ± 0.02
AF-06 6.3 ±0.11 1.6 ± 0.48
AF-07 5.7 ± 0.09
∗ <1.0 ± 0.00
∗∗
AF-08 6.1 ±0.04 <1.0 ± 0.00
∗∗
ACV (5 mg/kg) 5.4 ± 0.14
∗ <1.0 ± 0.00
∗∗
Values are mean ± standard error of the mean (SEM) of ﬁve mice.
∗P<. 01 and ∗∗P<. 001 versus control by Student’s t-test.
To assess the potential anti-HSV-1 activity of the three
propolis extracts in vitro, we performed a plaque reduction
assay in Vero cells. As shown in Table 2,t h eE C 50 values of
AF-06 and 07 were moderately but signiﬁcantly lower than
the CC50 values although the selectivity indexes (CC50/EC50)
of AF-06 and 07 were very lower than that of ACV. However,
the selectivity index of AF-08 was less than 0.9. Thus, it
is possible that AF-06 and 07 possess potential anti-HSV-1
activity in vitro.
3.4. Eﬀect of Propolis Extracts on DTH Reaction to HSV-1
Antigen. To evaluate the immunological eﬀect of the three
propolis extracts in mice infected with HSV-1, eﬀects of
the extracts on DTH reaction, which is one of the most
important defense systems in intradermal HSV-1 infection,
were examined [21–23]. As shown in Figure 3,A F - 0 6a n d0 8
augmented the DTH skin reaction, a major immune defense
response to intradermal HSV infection, at 36h and/or 48h
after challenge of HSV-1 antigen but AF-07 did not.
Table 3: Anti-HSV-1 activity of propolis extracts in Vero cells.
EC50(μg/mL) CC50(μg/mL) CC50/EC50
AF-06 61.0 ±0.2
∗ 93.9 ±1.81 . 5
AF-07 51.4 ±1.3
∗ 82.0 ±0.31 . 6
AF-08 >50 43.4 ±2.6 <0.9
ACV 0.48 ±0.05 >30 >62.5
Values are mean ± SEM of three independent experiments.
∗P< . 05 versus CC50 by Student’s t-test.
3.5. Eﬀects of Propolis Extracts on IFN-γ Production by
Splenocytes of Infected Mice. IFN-γ is a major mediator of
lymphocyte recruitment in DTH [27]. Oral administration
of AF-06, 07, and 08 was examined for their eﬀects on IFN-
γ production by HSV-1 antigen from splenocytes prepared
from mice infected intradermally with HSV-1. As shown in
Table 3, the oral administration of AF-08 was signiﬁcantly
eﬀective in augmenting IFN-γ production by HSV-1 antigen
from the splenocytes, but AF-06 and 07 were not. In infected
mice administered AF-08, the signiﬁcant increase of IFN-γ
production correlated with augmentation of the DTH skin
reactionbutdidnotininfectedmiceadministeredAF-06and
07.
On the other hand, IFN-γ production from splenocytes
prepared from HSV-1-infected mice without administration
of propolis extracts was examined in the presence of various
concentrations of the extracts with or without inactivated
HSV-1 antigen. As shown in Figure 4, AF-06 at 0.3 and
1μg/mL signiﬁcantly augmented IFN-γ production in the
presence ofinactivated HSV-1 antigenascompared with that
in its absence. AF-06 exhibited the bell-shaped concentration
dependency that is a characteristic of cytokine reaction by
its direct stimulation to splenocytes. However, AF-07 and6 Evidence-Based Complementary and Alternative Medicine
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Figure 3:Timecourse ofskinreactions to HSV-1antigenin miceinfected intradermallywithHSV-1.SevenHSV-1-infected mice ina group
were administered water (closed columns), AF-06 (opened columns), AF-07 (lightly dotted columns), or AF-08 (densely dotted columns),
and the mean percent swelling was determined at 24, 36, and 48h after injection of HSV antigen into footpads as described in text. ∗P<. 05
and ∗∗P<. 01 versus control by Student’s t-test. Bars indicate SEM.
08 failed to augment the production in the presence of the
antigen at all concentrations examined.
4.Discussion
Propolis is a natural product known worldwide as a folk
medicine and used as a dietary supplement because of its
wide range of biologicalactivities [1–9]. Ithas been adminis-
tered orally and applied for the improvement of symptoms
of viral infection. However, there has been little research
to elucidate the theoretical bases for the clinical eﬃcacy of
propolis. In this study, we tried to determine the basis of
the therapeutic eﬀects on herpetic skin lesions of propolis
using a cutaneous HSV-1 infection mouse model and found
that the ethanol extracts of Brazilian propolis AF-06, 07, and
08 exhibited therapeutically moderate eﬃcacy in limiting
herpetic lesionsinmice.Brazilianpropolishasbeenreported
tohaveachemicalcompositionandpharmacologicalactivity
that are diﬀerent from propolis produced in temperate zones
[3, 7–9, 28]. Even among Brazilian propolis, the chemical
compositiondependsontheareaandvegetationwhere itwas
harvested. Expectedly the HPLC patterns of compositions of
AF-05 and 07, in which artepillin C is a major component,
were similar, because they were harvested in similar area and
vegetation as shown in Table 1. This result was consistent
with that AF-05 and 07 physicochemically belong to a same
group that is diﬀerent from the groups of AF-06 and 08
[8, 26]. AF-06 and 08 were harvested in similar area but their
vegetations (Table 1) and HPLC patterns (Figure 1)w e r e
diﬀerent. Although we selected three propolis extracts (AF-
06, 07, and 08) that have diﬀerent compositions, all three
were eﬀective against cutaneous HSV-1 infection in mice.
Thus, Brazilian propolis may be characterized as having
possible antiherpes components in vivo.
The three diﬀerent propolis extracts moderately limited
herpetic skin lesions in the early phase of cutaneous HSV-
1i n f e c t i o n( Figure 2). We used 10mg/kg of extracts for oral
administration to mice. This dose for mice corresponds toEvidence-Based Complementary and Alternative Medicine 7
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Figure 4: Eﬀects of AF-06, 07, and 08 on IFN-γ production from splenocytes by inactivated HSV antigen (Table 4). Splenocytes were
prepared from intradermally HSV-1-infected mice on day 4 and incubated in the presence of various concentrations of extracts (0, 0.1, 0.3,
1, 3, 10, and 30μg/mL) and in the presence (closed columns) or absence (opened columns) of HSV antigen for 24h. IFN-γ levels in the
culture supernatants were measured by ELISA as described in text. ∗P<. 05 versus HSV(−)b yS t u d e n t ’ st-test. Bars indicate SEM.
Table 4: IFN-γ production by inactivated HSV antigens from
splenocytes of HSV-1-infected mice treated orally with propolis
extracts.
HSV− (pg/mL) HSV+ (pg/mL)
Control <15 <15
AF-06 <15 17.47 ± 8.18
AF-07 <15 <15
AF-08 <15 52.12 ± 15.87∗
Values are mean ± SEM of octuplicate wells prepared from splenocytes of
three mice.
∗P<. 005 versus control by Student’s t-test.
the conventional dose of propolis used for humans based
on body surface area. The virus titers in skin and brain of
infected mice administered AF-07 and 08 at this dose were
equivalent to that of 5mg/kg oral ACV treatment, to the
clinicaldoseforhumans(Table 1).Itsuggestedthepossibility
that oral administration of AF-07 and 08 could be used
clinically in combination with oral ACV treatment in the
early phase of cutaneous HSV-1 infection to improve the
eﬃcacy of ACV.
AmongAF-06,07,and08,AF-07and08weremoderately
eﬀective in reducing virus titers in the skin and/or brain
of infected mice (Table 1). AF-07 and 08 were possibly
eﬀective in producing anti-HSV-1 activity in mice. AF-07
showed modest anti-HSV-1 activity in vitro (Table 2), and
the anti-HSV-1 activity of AF-07 was also suggested to be
maintained in the skin and brain of infected mice after oral
administration. As the composition of AF-05 was similar to
thatofAF-07(Figure 1),itispossiblethatAF-05alsoexhibits
anti-HSV-1 activity in mice. In contrast with AF-07, AF-
08 did not exhibit anti-HSV-1 activity in vitro (Table 2)b u t
signiﬁcantly reduced virus titers in the brain of infected mice
(Table 1). It is possible that AF-08 has an immunological
activity contributing to the limitation of HSV-1 growth
and/or elimination of viruses in the brain. In the case of
AF-06, it was signiﬁcantly eﬀective against HSV-1 in vitro
(Table 2)b u tn o tin vivo (Table 1). The anti-HSV-1 activity8 Evidence-Based Complementary and Alternative Medicine
ofAF-06 exhibited in vitro was probablynoneﬀective inmice
after oral administration. However, AF-06 was eﬀective in
limiting the development of herpetic skin lesions (Figure 2).
AF-06 was suggested to have an immunological activity
associated with the limitation of herpetic skin lesions. Thus
all three propolis extracts used were suggested to have some
components showing anti-HSV-1 activity or immunological
activity leading the alleviation of herpetic symptoms.
The DTH skin reaction has been shown to be a major
defense system in the clearance of HSV-1 in mice infected
intradermally with HSV-1 [21, 23], although recovery
from intraperitoneal HSV-1 infection has been shown to
be mediated by cytotoxic T lymphocytes [22]. The oral
administration of AF-06 and 08 signiﬁcantly augmented
DTH skin reactions against inactivated HSV-1 antigen but
that of AF-07 did not (Figure 3). In intradermally HSV-
1-infected mice, DTH reaction has been reported to be
maximum between 24 and 48h after challenge [15, 21]. The
signiﬁcant augmentation of swelling at 36 and 48h after
challenge by AF-06 and 08 (Figure 3) was consistent with
the previous reports. Thus, AF-06 and 08 were suggested to
have components that act as biological response modiﬁers
(BRMs) for DTH reaction in intradermally HSV-1-infected
mice. In contrast to AF-06 and 08, AF-07 exhibited anti-
HSV-1 activity in vitro and in vivo (Tables 1 and 2)
and probably contains components that exhibit anti-HSV-1
activity rather than act as BRM.
IFN-γ has been reported to be a potent stimulator of
lymphocyte migration into skin and a major mediator of
lymphocyte recruitment in DTH [27]. The oral administra-
tion of AF-08 was signiﬁcantly eﬀective in elevating HSV-1
antigen-stimulated IFN-γ production from the splenocytes
of HSV-1-infected mice (Table 3). However, AF-08 failed to
directly augment the IFN-γ production from splenocytes
of HSV-1-infected mice in the presence of HSV-1 antigen
(Figure 4). Thus, AF-08 was suggested to have some com-
ponents that can be active as BRM in infected mice after
oral administration. On the other hand, AF-06 was not
signiﬁcantly eﬀective in augmenting IFN-γ production in
infected mice after oral administration (Table 3) but directly
augmented IFN-γ production from splenocytes in vitro
(Figure 4). This indicated that AF-06 has components that
can act directly on splenocytes as BRM in vitro.H o w e v e r ,
because AF-07 was not eﬀective in the DTH skin reaction
and IFN-γ production from splenocytes by HSV-1 antigen,
its eﬃcacy was conﬁrmed to be possibly due to anti-HSV-1
activity of the components. The DTH reaction against HSV-
1 antigen was reported to be mainly mediated by Lyt 1+2−
T - l y m p h o c y t es u b s e t si na ni n t r a d e r m a li n f e c t i o nm o d e l
[29, 30]. Macrophages activated by the T-lymphocytes may
be responsible for the DTH reaction [31]. Components of
AF-06 and 08 might have activated Lyt 1+2− T-lymphocyte
subsets or directly activated macrophages in the site of skin
lesions of infected mice.AF-06and 08were suggested tohave
components that act as BRM.
Brazilian propolis contains various kinds of ﬂavonoids
a n dp r e n y l a t e dp h e n y l p r o p a n o i d s[ 8, 26]. In this study,
artepillin C as a prenylated phenylpropanoid was a major
component in AF-05, 06, and 07 and chrysin as a ﬂavonoid
was a major component in AF-06 (Figure 1). These results
suggested that major components of Brazilian propolis are
ﬂavonoids and prenylated phenylpropanoids and supported
other works with Brazilian propolis [8, 26]. Brazilian propo-
lisisalsoknowntohavethewiderangeofbiologicalactivities
[2–5, 7, 9]. It may be worthwhile to further investigate
anti-HSV-1 or immunologically active compounds from
ﬂavonoids and prenylated phenylpropanoids that may be
involved in AF-05, 06, 07, and 08 used in this study.
We characterized the experimental bases of Brazilian
propolis treatment using an HSV-1 infection model in mice.
Together, all results indicate that Brazilian propolis showed
not only direct anti-HSV-1 activity but also immunolog-
ical activity against intradermal HSV-1 infection in mice.
Especially, the immunological activity associated with IFN-γ
production-inducing Th1 immunity in mice may contribute
to the elucidation of various pharmacological actions of
propolis in health and disease.
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